Clarifying Remanufacturing to Protect Patient Safety Act of 2022
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to provide for clarification of requirements for the remanufacturing of medical devices, and for other purposes.
2. Clarification of remanufacturing in definition
“(1) The term manufacture, preparation, propagation, compounding, or processing shall include the following:
“(A) Repackaging or otherwise changing the container, wrapper, or labeling of any drug package or device package in furtherance of the distribution of the drug or device from the original place of manufacture to the person who makes final delivery or sale to the ultimate consumer or user.
“(B) Remanufacturing of any finished device by engaging in any act that could significantly change the performance or safety specifications, or intended use, of the finished device, including by significantly changing—
“(i) a sterilization method;
“(ii) a reprocessing instruction;
“(iii) a control mechanism, operating principle, or energy input or output;
“(iv) the anatomical location of use; or
“(v) the design.”
“(6) The Secretary shall require that lists of devices reported pursuant to paragraph (2) specifically identify in any such list those devices that have been or are being remanufactured as described in subsection (a)(1)(B).”
3. Inspection of device remanufacturing establishments
“(G) Whether the establishment is registered as a remanufacturer or otherwise believed to be engaged in remanufacturing.”
“(iii) the number of establishments registered as remanufacturers that the Secretary inspected in the previous calendar year;”